Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3851236 | 0.87 | GBA1 (0.79) | ALDH1A1KMT2AMEN1CYP2C9MAPT | |
| SCHEMBL5205575 | 0.87 | GBA1 (0.79) | ALDH1A1KMT2AMEN1CYP2C9MAPT | |
| SCHEMBL5028416 | 0.83 | KMT2A (0.70) | ALDH1A1KMT2AMEN1CYP2C9LMNA | |
| SCHEMBL5028418 | 0.83 | KMT2A (0.70) | ALDH1A1KMT2AMEN1CYP2C9LMNA | |
| SCHEMBL3851498 | 0.82 | KMT2A (0.86) | ALDH1A1KMT2AMEN1CYP2C9LMNA | |
| SCHEMBL14606672 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1CYP2C9LMNA | |
| SCHEMBL14606617 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1CYP2C9LMNA | |
| SCHEMBL27917796 | 0.81 | ALDH1A1 (0.68) | ALDH1A1KMT2AMEN1CYP2C9LMNA | |
| SCHEMBL7699722 | 0.81 | KMT2A (0.68) | ALDH1A1KMT2AMEN1CYP2C9LMNA | |
| SCHEMBL3851560 | 0.80 | MEN1 (0.80) | ALDH1A1KMT2AMEN1CYP2C9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579504-B2 | ABCA1 elevating compounds | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070203245-A1 | ABCA1 elevating compounds | CV THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| WO-2007067817-A1 | ABCA1 ELEVATING COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203245-A1 | ABCA1 elevating compounds | ABCD3, ABCB4, CETP | ALDH1A1 1804/4885KMT2A 4193/4885MEN1 4424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.